Bridging Chemotherapy: Follicular Lymphoma, Mantle Cell Lymphoma, and CLL

Nico Gagelmann; John Gribben; Nicolaus Kröger

doi:10.1007/978-3-030-94353-0_23

Bridging Chemotherapy: Follicular Lymphoma, Mantle Cell Lymphoma, and CLL

Review

In: The EBMT/EHA CAR-T Cell Handbook [Internet]. Cham (CH): Springer; 2022. Chapter 23.

2022 Feb 7.

Authors

Nico Gagelmann¹, John Gribben², Nicolaus Kröger¹

Book Editors

Nicolaus Kröger¹, John Gribben², Christian Chabannon³, Ibrahim Yakoub-Agha⁴, Hermann Einsele⁵

Affiliations

¹ Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
² Bart’s Cancer Institute, Queen Mary University of London, London, UK

Book Affiliations

¹ Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
² Bart’s Cancer Institute, Queen Mary University of London, London, UK
³ Institut Paoli-Calmettes Comprehensive Cancer Center Aix-Marseille Université School of Medicine, Marseille, France
⁴ Maladies du Sang, Unité de Thérapie Cellulaire Centre hospitalier-Universitaire de Lille, Lille, France
⁵ Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Bayern, Germany

Excerpt

While lisocabtagene maraleucel (liso-cel) is the only product that is specifically approved to treat grade 3B follicular lymphoma (FL), specifically in aggressive lymphoma indications, to date, axi-cel is the first and only approved CAR-T product for indolent NHL.

Sections

References

Publication types

Review